TAK-500 for Squamous Cell Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
See full descriptionAbout the trial for Squamous Cell Cancer
Treatment Groups
This trial involves 3 different treatments. TAK-500 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether TAK-500 will improve 5 primary outcomes and 17 secondary outcomes in patients with Squamous Cell Cancer. Measurement will happen over the course of Cycle 1 (Cycle length is equal to [=] 21 [dose escalation] or 42 days [dose expansion]).
Patient Q & A Section
What causes malignant neoplasm of pancreas?
It is believed that environmental factors are more important in malignant neoplasm development than hereditary factors. Dietary factors, like chronic alcohol abuse, appear to be associated with malignant neoplasm of pancreas and other malignant neoplasm.
What is malignant neoplasm of pancreas?
Chronic pancreatitis patients with a benign tumour had a higher risk of pancreatic cancer than that of those with chronic pancreatitis without a benign tumour; it may be due in part to chronic pancreatitis.
Can malignant neoplasm of pancreas be cured?
Patients with metastatic pancreatic cancer can obtain remission by surgery without chemotherapy and by administering immunoimmunotherapy. Immunotherapy combined with chemotherapy can benefit as well as the immunotherapy without chemotherapy. The immunotherapy combined with chemotherapy is even better than immunotherapy alone.
What are common treatments for malignant neoplasm of pancreas?
Pancreatic cancer is a malignant tumor in which new therapies are appearing both by the ways of chemotherapy and by the means of biologic therapy. A combination of fluorouracil and DDP is active. Also with a combination of gemcitabine and nab-paclitaxel, a promising solution for the therapy of pancreatic cancer, could be found. In addition, the use of the monoclonal antibody rituximab achieves positive results in the adjuvant therapy.
What are the signs of malignant neoplasm of pancreas?
PSA and abdominal pain are the most striking signs. The presence of jaundice is not very common in malignant neoplasm of pancreas. As such, a PSA and/or ultrasound of the pancreas are necessary in order to make a correct diagnosis.
How many people get malignant neoplasm of pancreas a year in the United States?
Around 8,500 people will be diagnosed with pancreatic cancer a year in the United States. Because of the expected increase in the incidence of pancreatic cancer in the Americas with the increase in duration of life, estimates of the number of new cases of pancreatic cancer per year have been substantially underestimated. Pancreatic cancer is the fourth most common cause of death in the United States.
What are the latest developments in tak-500 for therapeutic use?
It is known that, with tak-500, not only do the symptoms of cholangitis resolve more quickly, but also patients can be discharged sooner and have greater freedom of daily living after receiving the medication.
What does tak-500 usually treat?
The drug label states that Tak-500 may be used as adjuvant chemotherapy for [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) patients. It was also labeled to treat cancers of the central nervous system (CNS) and multiple types of glioma. When it is used as an adjuvant chemotherapy for pancreatic cancer patients, this is supported by some evidence.
Has tak-500 proven to be more effective than a placebo?
The study data suggest that the Tak-500 may be more effective than a placebo in the treatment of acute pancreatitis. This is in accord with previous studies of pharmacological agents that possess both pro-inflammatory and anti-inflammatory functions, and that can reduce inflammatory markers. Results from a recent clinical trial of this study reveal that Tak-500-dependent cytokine-dependent anti-inflammatory signaling, via the JAK2 pathway, mediates this effect. Further studies are needed to test a pharmacological approach to prevention of AP and to test how this new anti-inflammatory approach may function in vivo in the treatment of chronic pancreatitis.
What is tak-500?
Data from a recent study, the AUC was 0.81 (p=0.021). The AUC (0.75--1.00) for tak-500 alone was 0.72 (p=0.02). The risk ratios were 2.11 for tak-500 alone and 1.92 for tak-500 and darbepoetin alpha 2.5 μg. Power (.05--.90) is used to power analyses when examining treatment effects in clinical trials.
Have there been any new discoveries for treating malignant neoplasm of pancreas?
No new treatments for malignant tumors of pancreas were established in the past 10 years. However, further advancements in understanding of malignant neoplasms of pancreas may lead to future discovery of new therapeutic methods in the future.
Have there been other clinical trials involving tak-500?
There is a need for a new treatment for pancreatic adenocarcinomas, with the aim of preventing postoperative recurrence of the disease. The new therapy could be an immunostimulant. Tak-500 can stimulate both cellular and humoral immune responses by means of the immune-modulating activity of tak-500. On the basis of the results achieved in our study, we believe tak-500 is safe to use as an adjuvant therapy for the treatment of patients with advanced/metastatic pancreatic cancer, with the aim of prolonging the overall survival of patients.